Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
NCT03943875Phase 4Completed
- Sponsor
- The University of Texas Medical Branch at Galveston
- Start
- Jun 2019
- Primary completion
- Jan 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (4 arms), sponsored by The University of Texas Medical Branch at Galveston. Primary endpoint: Human Papillomavirus (HPV) Type-specific Antibody Response for Types 6, 11, 16, 18, 31, 33, 45, 52, 58 at 12 months. Started Jun 2019; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03943875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943875.